Lots of industry people have been decrying what has been seen as a dearth of venture money for biotech startups in recent years. However, a recent analysis of the situation during 2011 suggests that all of the doom and gloom appears to be unfounded. And get this: Biotech venture investing saw significant growth last year, and even early rounds of financing picked up in the fourth quarter, according to research from OnBioVC.
As cited in Pharmalot, OnBioVC says biopharma companies secured $3.5 billion in venture capital in 2011, up 16% from the previous year. There was also a jump in the number of financing deals (160) versus 2010 (153). And, as in the past, biotech topped other life sciences sectors such as medical devices, diagnostics and biofuels in total capital raised by a wide margin. (For the record, FierceBiotech last month reported the surge in biotech venture investing last year with figures from the National Venture Capital Association and PriceWaterhouseCoopers.)
To read the full, original article click on this link: Biotech VC climate warmer than some thought - FierceBiotech
